Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Bladder Cancer, January 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 96 articles: HTML format

Single Articles

1. YANG CY, Ho SC, Chiu YW, Weng YH, et al
   Risk of death from bladder cancer in relation to long-term exposure to fine particulate air pollution in Taiwan.
   J Toxicol Environ Health A. 2026 Jan 2:1-10. doi: 10.1080/15287394.2025.2611423.
   PubMed    
   Abstract available
   
   

2. YAMAMOTO H, Oura S
   Possible Differentiation Between Recurrent Lymph Nodes of Bladder Cancer and Malignant Lymphoma on Ultrasound: A Case Report.
   Cureus. 2025;17:e98260.
   PubMed    
   Abstract available
   
   

3. SIKDER RK, Ellithi M, Uzzo RN, Weader DJ, et al
   Editor's Note: Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer.
   Mol Cancer Res. 2026;24:84.
   PubMed    
   
   
   

4. ANWAR I, Pandith AA, Rasool SUA, Manzoor U, et al
   Promoter hypermethylation drives a paradoxical up regulation of hTERT with prognostic implications in bladder cancer.
   Urol Oncol. 2025 Dec 31:110963. doi: 10.1016/j.urolonc.2025.
   PubMed    
   Abstract available
   
   

5. SORIA F, Liedberg F, Stahl E, Dominguez-Escrig JL, et al
   Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival
   Eur Urol Oncol. 2025 Dec 31:S2588-9311(25)00328.
   PubMed    
   Abstract available
   
   

6. LEE J, Jung H, Kim EG, Ahn J, et al
   Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer.
   Sci Adv. 2026;12:eady0041.
   PubMed    
   Abstract available
   
   

7. JURCZOK N, Dernbach G, Ebner B, Plage H, et al
   Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer.
   Eur Urol Oncol. 2025 Dec 30:S2588-9311(25)00333.
   PubMed    
   Abstract available
   
   

8. BIDI S, Nerli RB, Rangrez S, Ghagane SC, et al
   Association of SLC14A1C/T Polymorphisms in Patients with Bladder Cancer in Comparison with Healthy Controls.
   South Asian J Cancer. 2025;14:810-814.
   PubMed    
   Abstract available
   
   

9. SPITZER A, Aupperle-Lellbach H, Spitzer M, Weidle S, et al
   DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry-A Digital Quantitative Pilot Study.
   Vet Sci. 2025;12:1209.
   PubMed    
   Abstract available
   
   

10. WOLF I, Giess N, Roider C, Schultze-Seemann S, et al
    Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy.
    Molecules. 2025;30:4802.
    PubMed    
    Abstract available
    
    

11. KAYER A, Ozen A, Dinleyici EC
    Urinary Microbiota Composition in Treatment-Naive Bladder Cancer: A Case-Control Study with Tumor Invasiveness Stratification.
    Medicina (Kaunas). 2025;61:2240.
    PubMed    
    Abstract available
    
    

12. SONG B, Lee H, Lee S, Hong SK, et al
    Preoperative serum albumin level is associated with postoperative short- and long-term renal function deterioration in patients who underwent radical cystectomy for bladder cancer.
    Investig Clin Urol. 2026;67:24-31.
    PubMed    
    Abstract available
    
    

13. CERRATO C, Pandolfo SD, Kraft P, Ko DSC, et al
    Opportunistic salpingectomy during radical cystectomy for bladder cancer: A systematic review of the literature.
    Asian J Urol. 2025;12:471-477.
    PubMed    
    Abstract available
    
    

14. ANIS O, Bar V, Zundelevich A, Anil SM, et al
    Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich Cannabis sativa strains.
    Asian J Urol. 2025;12:534-543.
    PubMed    
    Abstract available
    
    

15. LAYMON M, Elsawy AA, Elsorougy A, Hashem A, et al
    Clinically lymph node-positive urothelial bladder cancer treated with upfront radical cystectomy: Diagnostic accuracy of MRI and long-term oncologic outcomes.
    Asian J Urol. 2025;12:520-528.
    PubMed    
    Abstract available
    
    

16. SONG M, Ren H, Wang L, Zhou Y, et al
    Beyond VI-RADS Uncertainty: Leveraging Spatiotemporal DCE-MRI to Predict Bladder Cancer Muscle Invasion.
    Bioengineering (Basel). 2025;12:1338.
    PubMed    
    Abstract available
    
    

17. CIGLIOLA A, Maiorano BA, Dengur D, Tateo V, et al
    The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
    Cancers (Basel). 2025;17:4017.
    PubMed    
    Abstract available
    
    

18. PLAGE H, Biernath N, Furlano K, Weinberger S, et al
    Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes.
    Cancers (Basel). 2025;17:3990.
    PubMed    
    Abstract available
    
    

19. HOSHI S, Meguro S, Makabe S, Onagi A, et al
    Immunosuppressive Role of Integrin beta8 in Recurrence After Bacillus Calmette-Guerin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2025;17:3964.
    PubMed    
    Abstract available
    
    

20. XIAO B, Zeng Q, Peng X, He Q, et al
    An interpretable machine learning model based on CT imaging for predicting lymphovascular invasion and survival in bladder urothelial carcinoma: a multicenter study.
    BMC Med Imaging. 2025;25:513.
    PubMed    
    Abstract available
    
    

21. LI C, Meng F, Lu C, Li A, et al
    A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.
    J Nanobiotechnology. 2025 Dec 29. doi: 10.1186/s12951-025-03935.
    PubMed    
    Abstract available
    
    

22. YANG CW, Yen CH, Chien TM, Yu SY, et al
    Excavatolide E triggers oxidative stress-associated apoptosis and DNA damage to inhibit bladder cancer cell proliferation.
    Mol Biol Rep. 2025;53:234.
    PubMed    
    Abstract available
    
    

23. LI L, Ren F, Liu Z, Tian X, et al
    Urothelial carcinoma following kidney transplantation: a narrative review of Chinese insights and challenges from pathogenesis to precision diagnosis and treatment.
    Front Immunol. 2025;16:1668356.
    PubMed    
    Abstract available
    
    

24. HO PARK J, Lee H, Lee S, Hong SK, et al
    Effect of early detubularization on urethro-intestinal anastomosis during robot-assisted radical cystectomy and intracorporeal neobladder among bladder cancer patients.
    Front Oncol. 2025;15:1680595.
    PubMed    
    Abstract available
    
    

25. KANEMOTO S, Yamamoto S, Hino K, Tsuboi K, et al
    Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report.
    IJU Case Rep. 2025;9:e70119.
    PubMed    
    Abstract available
    
    

26. PENUNURI A, Greenberg E, Phillips J, Katims AB, et al
    The Emerging Role of B Cells and Tertiary Lymphoid Structures in Bladder Cancer.
    Curr Urol Rep. 2025;27:3.
    PubMed    
    Abstract available
    
    

27. XU M, Yue S, Chen Z, Li R, et al
    hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities.
    Discov Oncol. 2025 Dec 28. doi: 10.1007/s12672-025-04355.
    PubMed    
    
    
    

28. WANG Y, Xue H, Xu S, Qin Y, et al
    Network toxicology analysis of hair dye components and their association with breast and bladder cancers.
    Afr J Reprod Health. 2025;29:204-216.
    PubMed    
    Abstract available
    
    

29. AHMADI SP, Sadabadi F, Khoshbin B, Sheikhi Z, et al
    Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study.
    BMC Urol. 2025 Dec 28. doi: 10.1186/s12894-025-02006.
    PubMed    
    
    
    

30. MOUSA MMA, Abou-Dobara MI, El-Zahed MM, El-Sherif ME, et al
    Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients.
    BMC Microbiol. 2025 Dec 27. doi: 10.1186/s12866-025-04572.
    PubMed    
    
    
    

31. ZHONG MY, Zou XC, Chen PH
    Explainable machine learning predicts overall survival in female bladder cancer patients after radical cystectomy.
    Discov Oncol. 2025 Dec 27. doi: 10.1007/s12672-025-04275.
    PubMed    
    Abstract available
    
    

32. ZHANG M, Chen C, Zeng X, Zhao Q, et al
    Application of computed diffusion-weighted imaging in vesical imaging reporting and data system assessment for bladder cancer.
    Abdom Radiol (NY). 2025 Dec 27. doi: 10.1007/s00261-025-05358.
    PubMed    
    Abstract available
    
    

33. TAN J, Wang Y, Huang J, Dong B, et al
    Exploration of the Prognostic Value of PANoptosis-Related Genes in Bladder Cancer.
    Am J Mens Health. 2025;19:15579883251404985.
    PubMed    
    Abstract available
    
    

34. HU Z, Zeng D, Zhao X, Luo Y, et al
    Global Disparities and Temporal Trends in Prostate, Bladder, and Kidney Cancer Burden Among Men: A Systematic Analysis of 204 Countries (1990-2021).
    Cancer Control. 2025;32:10732748251411011.
    PubMed    
    Abstract available
    
    

35. HUANG J, Chen D, Ji G, Ma J, et al
    ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway.
    J Transl Med. 2025;23:1427.
    PubMed    
    Abstract available
    
    

36. NAIR MS, Scarborough J, Reddy CA, Bommireddy AR, et al
    Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy.
    Clin Genitourin Cancer. 2025;24:102477.
    PubMed    
    Abstract available
    
    

37. OLUMOYIN K, El Naqa L, Rejniak K
    Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data.
    ArXiv [Preprint]. 2025 Dec 17:arXiv:2512.15706.
    PubMed    
    Abstract available
    
    

38. HANLON T, D'Andrea VD, Stelter I, Bekele R, et al
    Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization.
    Bladder Cancer. 2025;11:23523735251409720.
    PubMed    
    Abstract available
    
    

39. XUE Z, Qie Y, Shen C, Wu Z, et al
    Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Dec 24. doi: 10.1111/cas.70311.
    PubMed    
    Abstract available
    
    

40. LV J, Li K, Zhou J, Yu R, et al
    Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin.
    J Exp Clin Cancer Res. 2025;44:324.
    PubMed    
    Abstract available
    
    

41. ROESSLER N, Miszczyk M, Gontero P, Miyajima K, et al
    Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review.
    World J Urol. 2025;44:65.
    PubMed    
    Abstract available
    
    

42. LIU S, Liu T, Yang C, Mou Z, et al
    Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer.
    Cell Death Dis. 2025 Dec 24. doi: 10.1038/s41419-025-08369.
    PubMed    
    Abstract available
    
    

43. LIU H, Jiang X, Wang T, Zhang G, et al
    Low-dose corticomedullary phase CT urography with artificial intelligence iterative reconstruction for bladder cancer evaluation.
    Br J Radiol. 2025 Dec 24:tqaf315. doi: 10.1093.
    PubMed    
    Abstract available
    
    

44. PEKER P
    Correspondence regarding "Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German healt
    World J Urol. 2025;44:64.
    PubMed    
    
    
    

45. VANTAGGIATO L, Frisenda M, Shaba E, Splendore C, et al
    Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Stage-Specific Molecular Signatures and Prognostic Biomarkers.
    Proteomes. 2025;13:65.
    PubMed    
    Abstract available
    
    

46. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
    Incarcerated Patients Present with More Advanced Bladder Cancer Stage: A Statewide Analysis.
    Urol Pract. 2025 Dec 24:101097UPJ0000000000000961.
    PubMed    
    Abstract available
    
    

47. CARROLL TF, Bardot JP, David J, Zucker M, et al
    Compliance with Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer.
    Urol Pract. 2025 Dec 24:101097UPJ0000000000000962.
    PubMed    
    Abstract available
    
    

48. OZGUN G, Alexander A, Arbour G, Kollmannsberger C, et al
    Bladder Preservation in Muscle-Invasive Bladder Cancer: A Population-Based Analysis from British Columbia.
    Curr Oncol. 2025;32:699.
    PubMed    
    Abstract available
    
    

49. HU K, Ma X, Luo L, Li P, et al
    FGL1 as an Immune Checkpoint in the Immune Microenvironment of Bladder Cancer.
    J Immunother. 2025 Dec 26. doi: 10.1097/CJI.0000000000000595.
    PubMed    
    Abstract available
    
    

50. MIYAJIMA K, Matsukawa A, Yanagisawa T, Miszczyk M, et al
    Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Open Sci. 2025;83:54-63.
    PubMed    
    Abstract available
    
    

51. JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
    Bladder Cancer Burden in the USA: Population Scenarios for 2040.
    Eur Urol Open Sci. 2025;83:99-108.
    PubMed    
    Abstract available
    
    

52. ZHUANG J, Yu H, Cao Q, Bai R, et al
    Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.
    Eur Urol Open Sci. 2025;83:36-45.
    PubMed    
    Abstract available
    
    

53. XIANG J, Luo Y, Zhang B, Ke K, et al
    Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.
    Front Oncol. 2025;15:1670574.
    PubMed    
    Abstract available
    
    

54. ZHANG J, Wang Y, Yan Q, Wang H, et al
    SWI/SNF complex alterations predict immunotherapy response in bladder cancer.
    Front Immunol. 2025;16:1708324.
    PubMed    
    Abstract available
    
    

55. HAN Y, Peng J, Yan W, Wu Z, et al
    FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression.
    Hum Mutat. 2025;2025:5947612.
    PubMed    
    Abstract available
    
    

56. CHEN J, Fu Y, Zhang Z, Zhao J, et al
    Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.
    Int J Nanomedicine. 2025;20:15235-15275.
    PubMed    
    Abstract available
    
    

57. GONG J, Sun D, Zheng Y, Mao C, et al
    Dauricine Inhibits Macrophages M2 Polarization and Regulates the Progression and Ferroptosis via HCK/IDO1 in Urinary Bladder Cancer.
    Food Sci Nutr. 2025;13:e71341.
    PubMed    
    Abstract available
    
    

58. CHEN D, Li Z, Sui Y, Zeng Y, et al
    The efficacy and safety of interval and post-reTURBT intravesical therapy for bladder cancer.
    iScience. 2025;28:114152.
    PubMed    
    Abstract available
    
    

59. LI Q, Chen QF, Liao NQ
    Graph Neural Network-Based Multi-Scale Whole Slide Image Fusion for pT Staging of Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70292.
    PubMed    
    Abstract available
    
    

60. LI M, Liu T, Shi J, Zhou F, et al
    USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer.
    J Exp Clin Cancer Res. 2025 Dec 23. doi: 10.1186/s13046-025-03621.
    PubMed    
    
    
    

61. ZHI L, Yuan L
    Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/beta-catenin axis.
    Mamm Genome. 2025;37:20.
    PubMed    
    Abstract available
    
    

62. GOUHIZOUN O, Pattou M, Guena F, Khaddad A, et al
    Diagnostic accuracy of [18F]-FDG-PET/CT for lymph node staging in bladder cancer prior to radical cystectomy.
    World J Urol. 2025;44:59.
    PubMed    
    
    
    

63. D'ALESSIO I, Siloche D, Civilini E, Bissacco D, et al
    Aortic complications after treatment with bacillus Calmette-Guerin: a tertiary hospital experience and an update of the literature.
    J Cardiovasc Surg (Torino). 2025;66:532-542.
    PubMed    
    Abstract available
    
    

64. DONG W, Bi J, Liu H, Yan D, et al
    Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.
    Mol Cancer. 2025;24:309.
    PubMed    
    
    
    

65. WANG C, Li K, Wan S, Chen S, et al
    TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1.
    Cell Death Dis. 2025;16:923.
    PubMed    
    Abstract available
    
    

66. YANG H, Liu X, Nie J, Wu S, et al
    USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer.
    Cell Death Dis. 2025 Dec 23. doi: 10.1038/s41419-025-08297.
    PubMed    
    Abstract available
    
    

67. ZHAO X, Liu H, Wang C, Guo F, et al
    Development of a prognostic model related to mitochondria and programmed cell death-related genes in bladder cancer.
    Front Genet. 2025;16:1615167.
    PubMed    
    Abstract available
    
    

68. LING Z, He S, Li T, Zhang J, et al
    Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy.
    Hum Mutat. 2025;2025:5569005.
    PubMed    
    Abstract available
    
    

69. WENG R, Phung TAT, Bell R, Dyrskjot L, et al
    Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancer.
    BJUI Compass. 2025;6:e70131.
    PubMed    
    Abstract available
    
    

70. MARTEL A, Raue L, Avogbe PH, Raisch J, et al
    Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow-up.
    BJUI Compass. 2025;6:e70124.
    PubMed    
    Abstract available
    
    

71. LI C, Lv G, Xiong Z, Wang Z, et al
    Ginsenoside Rh2 Suppresses the Fanconi Anemia Pathway by Inhibiting NF-kappaB-Mediated FANCL Transcription in Bladder Cancer.
    Dose Response. 2025;23:15593258251411761.
    PubMed    
    Abstract available
    
    

72. DI SPIRITO A, Zuccolotto G, Tosi A, Balkhi S, et al
    Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.
    Front Cell Dev Biol. 2025;13:1719978.
    PubMed    
    Abstract available
    
    

73. WANG JM, Xie HY, Zhang FH, Shu X, et al
    Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization.
    J Hematol Oncol. 2025;18:110.
    PubMed    
    Abstract available
    
    

74. JANENZ J, Leipe A, Urban N, Schaefer M, et al
    Activation of TRPV3 channels in bladder cancer cells stimulates ATP release.
    Mol Pharmacol. 2025;108:100096.
    PubMed    
    Abstract available
    
    

75. LI G, Tatarano S, Yoshino H, Saito S, et al
    Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition.
    Mol Oncol. 2025 Dec 21. doi: 10.1002/1878-0261.70187.
    PubMed    
    Abstract available
    
    

76. JAZAYERI SB, DiNatale RG, Guske C, Harrs C, et al
    Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design.
    Eur Urol Focus. 2025 Dec 19:S2405-4569(25)00367.
    PubMed    
    Abstract available
    
    

77. JIANG L, Ge W, Feng R, Ji L, et al
    Innovative AI model for bladder cancer diagnosis.
    Discov Oncol. 2025 Dec 20. doi: 10.1007/s12672-025-04278.
    PubMed    
    Abstract available
    
    

78. SHI C, Xu J, Chen Q, Gao X, et al
    Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma.
    Clin Epigenetics. 2025;17:204.
    PubMed    
    Abstract available
    
    

79. XU C, Ying W, He Y, Wu Y, et al
    Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.
    Clin Epigenetics. 2025;17:203.
    PubMed    
    Abstract available
    
    

80. JIANG Y, Xu C, He W, Zhang C, et al
    First-line therapies analysis in advanced/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq.
    Int Immunopharmacol. 2026;169:116060.
    PubMed    
    Abstract available
    
    

81. MAIORANO BA, Cigliola A, Tateo V, Mercinelli C, et al
    Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.
    ESMO Open. 2025;10:105862.
    PubMed    
    Abstract available
    
    

82. GALSKY MD, Gschwend JE, Milowsky MI, Schenker M, et al
    Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
    Ann Oncol. 2026;37:69-78.
    PubMed    
    Abstract available
    
    

83. CAINI S, Cosma C, Aprea MC, Saieva C, et al
    Heavy metals levels in pre-diagnostic serum of nonsmokers with cancer of the lung, bladder and prostate, and paired individuals.
    Arch Environ Occup Health. 2025;80:303-307.
    PubMed    
    Abstract available
    
    

84. SHAMSEDDINE A, Abbas N, Temraz S, Al Darazi M, et al
    Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01).
    Future Oncol. 2025;21:3873-3884.
    PubMed    
    Abstract available
    
    

85. PANER GP, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, et al
    The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder.
    Adv Anat Pathol. 2026;33:1-16.
    PubMed    
    Abstract available
    
    

86. WAI R, Sheahen B, Thomas B
    Severe itch from miliaria managed with propantheline: a case report.
    BMJ Support Palliat Care. 2025;16:85-87.
    PubMed    
    Abstract available
    
    

87. SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
    Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
    PubMed    
    Abstract available
    
    

88. MENNES J, Akand M, Benijts R, Baekelandt L, et al
    Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
    PubMed    
    Abstract available
    
    

89. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
    Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
    Eur Urol. 2025 Dec 31:S0302-2838(25)04877-8. doi: 10.1016/j.eururo.2025.
    PubMed    
    Abstract available
    
    

90. GALLAGHER K, MacLennan S, Bhatt N, Clement K, et al
    RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
    Eur Urol. 2025 Dec 10:S0302-2838(25)04736-0. doi: 10.1016/j.eururo.2025.09.4174.
    PubMed    
    Abstract available
    
    

91. FILHO AM, Briganti A, Jemal A, Bray F, et al
    Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
    Eur Urol. 2025 Dec 19:S0302-2838(25)04864-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    Abstract available
    
    

92. DU J, Shen H, Zeng T, Liu W, et al
    Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next?generation antibody-drug conjugates (Review).
    Int J Oncol. 2026;68:28.
    PubMed    
    Abstract available
    
    

93. TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
    Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial.
    Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70328.
    PubMed    
    Abstract available
    
    

94. FIORENTINO V
    Editorial Comment to "Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Non-Muscular-Invasive Urothelial Bladder Cancer".
    Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70332.
    PubMed    
    
    
    

95. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
    Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
    PubMed    
    Abstract available
    
    

96. YANG IN, Liang CA, Wu CC, Xu QS, et al
    Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
    BMC Cancer. 2025;25:1900.
    PubMed    
    Abstract available